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Are PTH levels related to oxidative stress and inflammation 
in chronic kidney disease patients on hemodialysis?
Os níveis de PTH estão relacionados com estresse oxidativo e 
inflamação em pacientes renais crônicos em hemodiálise?
Introdução: Pacientes com doença renal em 
estágio terminal têm níveis de inflamação e 
estresse oxidativo maiores do que a população 
geral. Muitos fatores contribuem para isso, 
e o hormônio paratireoidiano (PTH) é um 
deles. Objetivo: Estudo foi realizado para 
avaliar a relação entre os níveis de PTH e 
níveis de inflamação e estresse oxidativo 
em pacientes em hemodiálise. Métodos: 
estudo transversal com pacientes de duas 
unidades de hemodiálise de Londrina, 
Brasil. Pacientes com condições causadoras 
de inflamação e estresse oxidativo foram 
exclusos. Níveis plasmáticos de PTH e 
parâmetros bioquímicos de inflamação 
(interleucina 1 e 6, fator de necrose tumoral 
alfa) e estresse oxidativo (capacidade 
antioxidante plasmática total, dialdeído 
malônico, hidroperoxidação lipídica, 
produtos avançados da degradação 
proteica, quantificação de metabólitos 
de óxido nítrico e 8-isoprostano) foram 
dosados antes da sessão de hemodiálise. 
Realizou-se análise de correlação entre 
os níveis de PTH - tanto como variável 
continua como variável categórica em 
tercis - e os parâmetros de inflamação e 
estresse oxidativo. Resultados: Não houve 
correlação do PTH com nenhum dos 
parâmetros testados, nem como variável 
contínua, nem como categórica. Conclusão: 
Neste estudo descritivo, os resultados 
sugerem que a inflamação e o estresse 
oxidativo em pacientes em hemodiálise 
provavelmente tem origem em mecanismos 
que não incluem o hiperparatireoidismo 
secundário.
Resumo
Introduction: Patients at end stage renal 
disease have higher levels of inflammation 
and oxidative stress than the general 
population. Many factors contribute to 
these issues, and the parathyroid hormone 
(PTH) is also implicated. Objective: The 
study was conducted in order to assess 
the relationship between PTH levels and 
inflammation and oxidative stress in 
hemodialysis patients. Methods: Cross-
sectional study with patients of two 
hemodialysis facilities in Londrina, Brazil. 
Patients with other conditions known to 
generate oxidative stress and inflammation 
were excluded. Blood levels of PTH and 
biochemical parameters of inflammation 
(interleukins 1 and 6, tumor necrosis 
factor-alpha) and oxidative stress (total 
plasma antioxidant capacity, malonic 
dialdehyde, lipid hydroperoxidation, 
advanced oxidation protein products, 
quantification of nitric oxide metabolites, 
and 8-isoprostane) were measured before a 
dialysis session. Then, we made correlation 
analyses between PTH levels - either as 
the continuous variable or categorized 
into tertiles-, and inflammatory and 
oxidative stress biomarkers. Results: 
PTH did not show any correlation with 
the tested inflammation and oxidative 
stress parameters, nor as continuous 
variable neither as categorical variable. 
Conclusion: In this descriptive study, the 
results suggest that the inflammation and 
oxidative stress of hemodialysis patients 
probably arise from mechanisms other 
than secondary hyperparathyroidism.
AbstRAct
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Palavras-chave: hiperparatireoidismo; es-
tresse oxidativo; inflamação; insuficiência 
renal crônica.
Keywords: hyperparathyroidism; inflam-
mation; oxidative stress; renal insufficien-
cy, chronic.
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IntRoductIon
Individuals with chronic kidney disease (CKD) 
undergoing dialysis have a mortality rate that is 20-
100 times higher than that of the normal population, 
with cardiovascular disease being the major 
contributor to this excess mortality.1 Traditional 
cardiovascular risk factors (e.g., hypertension, 
diabetes mellitus, smoking, dyslipidemia, and 
sedentary lifestyle, among others) are common in 
this population, but these factors do not fully explain 
this high mortality. Other nontraditional factors 
contribute to the increased risk of cardiovascular 
mortality in these patients, including disorders of 
bone and mineral metabolism in CKD (CKD-MBD), 
chronic inflammation, and oxidative stress.2,3
Secondary hyperparathyroidism (SHPT) is part 
of CKD-MBD and is characterized by high levels of 
parathyroid hormone (PTH) associated with high-
turnover bone disease and vascular calcification. 
In high levels, PTH acts as an uremic toxin and 
contributes to bone loss, vascular and valvular 
calcification, anemia, cardiomyopathy, hypertension, 
and glucose intolerance.4
Regarding oxidative stress, it can be defined as 
tissue damage resulting from an imbalance between 
the generation of excessive oxidizing components 
and insufficient production of antioxidant defense 
mechanisms.5 Although an essential mechanism in 
inflammation, tissue wound and repair and combat 
against microorganisms and cancer cells, the excess 
of oxidative substances is maladaptative.6
In this way, states of increased generation of 
reactive oxygen species (ROS) lead to inflammatory 
states, since ROS are released from monocytes and 
polymorphonuclear cells with pro-inflammatory 
cytokines, which amplify, in turn, the generation 
of oxidants.7 Chronic kidney patients represent a 
population highly subjected to inflammation states 
and increased oxidative stress, either by its own 
characteristics (high prevalence of diabetes mellitus 
and advanced age, either by characteristics related to 
uremia and therapy dialysis, such as time on dialysis,8,9 
compatibility of dialysis membranes, exposure to 
endotoxins and parenteral administration of iron.10
A potential role of hyperparathyroidism in 
the genesis of inflammation/oxidative stress 
is suggested by the demonstration of direct 
relationship between PTH levels and inflammatory 
markers in general population and in patients with 
primary hyperparathyroidism.11-14 Furthermore, 
other authors demonstrated, in cases of secondary 
aldosteronism found in patients with congestive 
heart failure, a development of secondary 
hyperparathyroidism state, which leads to a rise in 
intracellular calcium concentration and consequently 
increased production of reactive oxygen species.15,16 
Additionally, parathyroidectomy reduced oxidative 
stress in rats with secondary hyperparathyroidism 
induced by aldosterone-NaCl treatment,15 and in a 
patient with primary hyperparathyroidism.17
However, other conflicting data exist regarding 
the correlation between inflammation and PTH 
levels, at least in non dialysis patients.18,19 In 
CKD patients, low PTH levels are associated with 
inflammation and oxidative stress, possible as a result 
of Malnutrition Inflammation Atherosclerosis (MIA) 
syndrome.20 To the best of our knowledge, there is 
only small studies that looked upon the severity of 
secondary hyperparathyroidism and oxidative stress 
in hemodialysis patients.21-23
Therefore, the purpose of this study was to 
evaluate possible correlations between PTH levels 
and inflammation and oxidative stress biomarkers, 
and PTH levels and some routine laboratory tests in 
hemodialysis patients.
mAteRIAls And methods
Design anD population
We performed a cross-sectional study in two 
hemodialysis units. Patients were recruited between 
May and July 2012. Inclusion criteria were as 
follows: age 18 years or older and on hemodialysis 
with arteriovenous fistula (native or graft) for at 
least 3 months. Exclusion criteria were previous 
parathyroidectomy and conditions known to generate 
oxidative stress and inflammation, as follows: 
hemodialysis with temporary central venous catheter, 
neoplasm, active infection that caused hospitalization 
in the 15 days before blood collection, hepatitis B or 
C and human immunodeficiency virus.
Of the 155 selected patients who met the inclusion 
criteria, 23 patients were withdrawn from the final 
analysis, due to lack of material to complete analysis 
(11), death (4), active infection during blood collection 
(4), inadequate blood collection (2), introduction of 
a venous catheter for hemodialysis (1), and partial 
recovery of renal function leading to discharge from 
the dialysis center (1).
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Dialysis sessions took between 210 to 240 
minutes, with a blood flow of 300 to 450 ml/min 
and dialysate at 500 ml/min, three times per week. 
The dialyzers were hollow fiber cellulose triacetate 
(surface area depended on the patient’s body surface), 
with pure water in the dialysate. The dialysis target 
was an unbalanced Kt/V of 1.2. Participants provided 
written informed consent prior to participation. The 
study was approved and registered (No. 07791) by 
the local Ethics Committee.
Data collection
Through chart review and interviews, we collected 
demographic data and information regarding time on 
dialysis, underlying disease, comorbidities, current 
smoking status (yes or no) and medication use. The 
mean dose of EPO (in U/kg/week) was based on the 
last 30 days before blood sample collection.
Biochemical analyses
We obtained blood samples of patients (~20 mL) at the 
time of puncture for initiation of the first hemodialysis 
session in the week, after 8 hours of fasting. Samples 
were collected in vacuum tubes (Vacutainer®, 
Franklin Lakes, NJ, USA) without anticoagulant, 
centrifuged at 830 g for 15 minutes and the resulting 
serum stored at -70 °C until analysis. All patients with 
regular parenteral iron use during hemodialysis had 
suspended use of this medication for at least 1 week 
before the collection procedure.
laBoratory parameters
We measured serum creatinine, urea before and 
after the session (for calculation of efficiency of 
dialysis or Kt/V), ferritin, hemoglobin, calcium, 
phosphorus, alkaline phosphatase, uric acid, and 
albumin according to standard techniques. Intact 
parathyroid hormone (iPTH) was measured by 
electrochemiluminescence (Modular Analytics E170, 
Roche, Mannheim, Germany). To avoid variation 
in nomenclature throughout this paper, we have 
chosen the use of the acronym PTH, even though 
the performed dosage was of the intact molecule. We 
measured levels of vitamin D (25-hydroxyvitamin D)
by chemiluminescence (Architect i2000, Abbott, IL, 
USA).
inflammatory parameters
Levels of interleukin (IL)-1, IL-6, and tumor necrosis 
factor alpha (TNF-α) were measured by ELISA.
oxiDative stress parameters
Oxidative stress was analyzed through the levels of 
the total plasma antioxidant capacity (TRAP), lipid 
hydroperoxidation (FOX), nitric oxide metabolites 
(NOx), malonic dialdehyde (MDA), advanced oxidation 
protein products (AOPPs) and 8-isoprostane. The 
FOX level was quantified using the spectrophotometric 
technique described by Jiang et al.,24 based on the 
oxidation of ferrous to ferric ions under acidic conditions 
by peroxides. Peroxide reacts with the indicator dye 
(xylenol orange) to produce a colored complex that is 
read by spectrophotometry (Helios α ThermoSpectronic®, 
Waltham, MA, USA) at 560 nm.
NOx levels were assessed indirectly by 
determining the concentration of plasma nitrites, 
using an adaptation of the method described by 
Navarro-Gonzálvez et al.25 The method is based on 
the reduction of nitrate to nitrite, mediated by redox 
reactions between nitrate in the sample and system with 
copper-cadmium reagents, resulting in diazotization. 
The compound formed by complexation with Griess 
reagent is detected colorimetrically at 550 nm.
TRAP was measured by chemiluminescence based 
on an adaptation of the method described by Repetto 
et al.26 The 2,2’ azo-bis rapidly generates peroxyl 
radicals via interaction with carbon-centered radicals 
and molecular oxygen. These free radicals react with 
luminol (which acts as an amplifier), producing 
chemiluminescence. The addition of plasma reduces 
the baseline levels of chemiluminescence for a 
period of time (induction time) proportional to the 
concentration of plasma antioxidants. Once the free 
radicals regenerate, chemiluminescence returns to its 
initial levels. The system was calibrated with a vitamin 
E analogue (Trolox). A comparison of the induction 
time after the additions of Trolox and plasma gives 
TRAP values of Trolox equivalents. The obtained 
values were corrected for serum uric acid levels.
To quantify AOPPs, we used the method 
described by Witko-Sarsat et al.,27 based on the 
reaction of oxidized proteins with potassium iodide 
under acidic conditions. We read the absorbance 
of the reaction immediately in a spectrophotometer 
(Helios α ThermoSpectronic®) at 340 nm. To assess 
levels of serum MDA, we modified the method 
described by Bastos et al.28 The formation of MDA 
occurs by decomposition of lipid hydroperoxides. 
Its concentration has been used to estimate the 
intensity of lipid peroxidation in cells and tissues. 
This method consists of measuring a pink chromogen 
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formed by the reaction of MDA with two molecules 
of thiobarbituric acid under acidic conditions and 
at high temperatures, with quantification by high 
performance liquid chromatography (HPLC). Finally, 
we measured 8-isoprostane by enzyme immunoassay 
using commercial kits from Cayman Chemical 
Company (Ann Arbor, Michigan, USA). For all the 
parameters of inflammation an oxidative stress 
measured, we did not insert a normality range due 
to the lack of validation regarding normal values in 
CKD population.
statistical analysis
Quantitative variables were expressed as mean ± 
standard deviation (SD) or median and interquartile 
range (IQR), depending on the normality of the data. 
Spearman correlation coefficient analysis was used 
to test the possible relations between PTH levels and 
other continuous variables. Comparison between 
inflammatory and oxidative stress biomarkers 
between groups classified according to tertiles of PTH 
levels was tested using Kruskal-Wallis test. The level 
of significance was 5% (p < 0.05). Statistical analysis 
was performed using SPSS version 19 (SPSS, Chicago, 
IL, USA).
Results
Of the 155 patients selected for the study, 132 
were included in the statistical analysis. All patients 
had their parameters of oxidative stress measured. 
General patient characteristics are shown in Tables 
1 and 2. The patient population contained a high 
prevalence of male, caucasian patients, with a mean 
age of 55 years. The median dialysis vintage was 
34.5 months. The prevalence of diabetes mellitus was 
31.8%. The most common baseline renal disease was 
hypertensive nephrosclerosis, followed by chronic 
glomerulonephritis and diabetic nephropathy. The 
median of PTH was 326 pg/mL. About other relevant 
laboratorial data, we found a high prevalence of 
vitamin D insufficiency/deficiency - almost 90% - 
with a median of 24.5 ng/mL.
Correlation analysis between PTH levels and 
inflammatory markers (IL-1, IL-6 and TNF-α) or 
oxidative stress (8-isoprostane, NOx, MDA, FOX, 
AOPP and TRAP) did not show any statistically 
significant correlation (Table 3). Due to different 
definitions of abnormal high levels in clinical practice 
supported by KDIGO and KDOQI, we performed an 
tAble1 general patients characteristics
Variable results
Male (%) 92 (69.7%)
Age (years) 55.1 ± 14.8
Dialysis vintage (months) 34.5 (18-74.7)
Race (%)
White 97 (73.5%)
Afroamericans 19 (14.4%)
Others 16 (12.1%)
CKD etiology (%)
HN 45 (34.1%)
CGN 35 (26.5%)
DN 34 (25.8%)
ADPKD 4 (3.0%)
Others 14 (10.6%)
MBP (mmHg) 97.3 ± 9.1
BMI 23.4 (20.8-27.7)
Current smoking (%) 19 (14.4%)
Diabetic patients (%) 42 (31.8%)
Patients on statins (%) 33 (25.0%)
ACEI/ARB (%) 69 (52.3%)
Calcitriol (%) 50 (37.9%)
EPO dose (U/kg/sem) 115.7 (0-178.7)
Results expressed as mean ± SD or median and interquartile range. 
CKD: Chronic Kidney Disease; HN: Hypertensive Nephrosclerosis; 
DN: Diabetic Nephropaty; CGN: Chronic Glomerulonephritis; ADPKD: 
Autossomic Dominant Polycistic Kidney Disease; MBP: Mean Blood 
Pressure; BMI: Body Mass Index; ACEI: Angiotensin Converting 
Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; EPO: 
Erythropoietin.
additional analysis categorizing PTH in tertiles, which 
also showed no significant statistical association with 
the biomarkers assessed (Table 4).
Correlation between PTH levels (as the continuous 
variable) and hemoglobin, ferritin, EPO dose, calcium, 
phosphorus, vitamin D, serum albumin, or alkaline 
phosphatase showed a weak positive correlation with 
PTH levels and phosphorus (Spearman, ρ = 0.219, p 
= 0.01) and a moderate positive correlation with PTH 
and alkaline phosphatase (Spearman, ρ = 0.455, p < 
0.001) (Table 5).
dIscussIon
The present study aimed at correlating PTH levels 
with some parameters of inflammation and oxidative 
stress in chronic renal failure patients on hemodialysis. 
Surprisingly, PTH as a continuous variable showed no 
correlation with the analyzed parameters. Likewise, 
levels of inflammation and oxidative stress markers 
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tAble 2 patients laBoratorial Data
Variable results
Hemoglobin (12-15 g/dL) 11.5 (10-12.5)
Creatinine (0,7-1,3 mg/dL) 9.1 ± 3.0
PTH (15-65 pg/mL) 326 (136-661.3)
Kt/V (> 1,2) 1.3 ± 0.3
Calcium (8,4-9,5 mg/dL) 8.8 (8.5-9.3)
Phosphorus (3,5-5,5 mg/dL) 5.6 (4.3-7.0)
Alkaline Phosphatase (40-130 U/L) 129 (95.3-180.5)
Ferritin (200-500 ng/mL) 772.4 (475.1-1041.5)
25(OH)D (> 30 ng/mL) 24.5 (19.5-28.4)
Albumin (3,5-5,2 g/dL) 4.2 (3.9-4.4)
IL-1 (pg/mL) 2 (2-2)
IL-6 (pg/mL) 3.8 (1.7-7.7)
TNF-α (pg/mL) 2 (2-49.8)
MDA (nM/mg protein) 78.8 (64.2-96.8)
TRAP/URCA (trolox) 171.3 ± 30.9
NOx (µM) 11.3 (8.9-15.9)
AOPP (μmol/L) 154.3 (123.7-202.6)
FOX (mM) 0.82 (0.65-0.97)
8-isoprostane (pg/mL) 74.6 (25.6-193.0)
Results expressed as mean ± SD or median and interquartile range. 
Kt/V: Dialytic adequacy; 25(OH)D: Vitamin D; IL-1 and 6: Interleukin 
1 and 6; TNF-α: Tumor Necrosis Factor alpha; MDA: Malonic 
Dialdehyde; TRAP: Total Plasma Antioxidant Capacity; URCA: Uric 
Acid; NOx: Nitric Oxide metabolites; AOPP: Advanced Oxidation 
Protein Products; FOX: Lipid Hydroperoxidation.
tAble 3 spearman coefficient correlation Between parathyroiD hormone anD oxiDative stress/inflammation  
 Biomarkers
PTH IL-1 IL-6 TNF-α MDA TRAP NOx AOPP FOX 8-Iso
Correlation 
coeficiente
0.047 -0.126 0.076 0.072 -0.112 0.060 0.118 0.079 0.043
Significancy 0.591 0.148 0.389 0.412 0.202 0.492 0.179 0.369 0.622
PTH: Parathyroid Hormone; IL-1 and 6: Interleukin 1 and 6; TNF-α: Tumor Necrosis Factor alpha; MDA: Malonic Dialdehyde; TRAP: Total Plasma 
Antioxidant Capacity (corrected for serum uric acid); NOx: Nitric Oxide metabolites; AOPP: Advanced Oxidation Protein Products; FOX: Lipid 
Hydroperoxidation; 8-Iso: 8-Isoprostane.
of improvement,17 deterioration,29 or unchanged19 
inflammatory markers after parathyroidectomy in 
patients with primary HPT. Almqvist et al.29 analyzed 
45 patients with primary hyperparathyroidism 
and normal renal function. Serum concentrations 
of IL-6, C-reactive protein (CRP) and erythrocyte 
sedimentation rate were measured at baseline and 
one year after parathyroidectomy. They found an 
increase in serum concentrations of these biomarkers 
of inflammation after the surgery.
Ogard et al.,19 in a similar population, did not find 
any correlation between serum levels of PTH after 
parathyroidectomy and markers of inflammation 
(IL-6, CRP, TNF-alpha). Finally, Navarro-González 
et al.18 did not find this direct relationship in non-
dialysis patients (stages 3 and 4 of chronic kidney 
disease).
Conversely, two longitudinal studies brought 
different data about the relationship among PTH, 
inflammation and oxidative stress. Wu et al showed 
in a study with 25 hemodialysis patients on high levels 
of PTH compared with 20 controls that the treatment 
with calcitriol for 16 weeks reduced not only the levels 
of PTH, but also decreased inflammatory (CRP and 
IL-6, CD4+ cytokines) and oxidative stress markers 
(TRAP) with statistical significance.22
Lu et al.,23 in a trial with a similar study design 
with 24 hemodialysis patients searching for levels of 
IL-6 and markers of bone remodeling, found lower 
levels of IL-6 compared to the baseline after 16 
weeks of intravenous calcitriol treatment, in parallel 
with PTH reduction. The authors suggested that 
the calcitriol reducing effect over the inflammatory 
markers is a result of the decrease in PTH levels and 
the pleiotropic effects of calcitriol.
In the same way, patients with primary HPT and 
HPT secondary to states of aldosteronism (found, for 
instance, in patients with congestive heart failure) 
also present exacerbated inflammatory state. The 
explanation for this exacerbated inflammatory 
were similar between PTH levels tertiles. Noyan 
et al.21, in a trial with 50 hemodialysis patients and 
20 control subjects, found similar results. In their 
study, dialysis patients were categorized into two 
groups according to PTH levels (> 300 pg/mL and < 
300 pg/mL). Oxidative stress was evaluated with two 
biomarkers (AOPP and MDA), plus myeloperoxidase 
activity (pro-oxidant) and catalase activity and 
ascorbic acid (antioxidants).
They found just a decrease in catalase activity in 
patients with PTH > 300 pg/mL, without any additional 
effect of PTH levels in ROS generation. Yet, adding 
more controversies to the issue, there are reports 
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tAble 4 relationship Between parathyroiD hormone tertiles anD parameters of inflammation anD oxiDative  
 stress
PTH < 198 198 ≤ PTH ≤ 517 PTH > 517 Test
Variables Median Median Median Kruskal-Wallis p-Value
IL-1 2.00 2.00 2.00 0.072 0.965
IL-6 3.74 4.72 3.44 2.274 0.321
TNF-α 2.00 2.00 2.00 0.595 0.743
MDA 75.60 81.60 75.77 1.913 0.384
TRAP 174.95 162.85 166.23 1.015 0.602
NOx 10.44 11.30 12.77 2.015 0.365
AOPP 150.72 135.45 157.46 2.654 0.265
FOX 0.83 0.80 0.88 4.063 0.131
8-Iso 69.20 82.20 76.10 0.051 0.975
PTH: Parathyroid Hormone; IL-1 and 6: Interleukin 1 and 6; TNF-α: Tumor Necrosis Factor alpha; MDA: Malonic Dialdehyde; TRAP: Total Plasma 
Antioxidant Capacity (corrected for serum uric acid); NOx: Nitric Oxide metabolites; AOPP: Advanced Oxidation Protein Products; FOX: Lipid 
Hydroperoxidation; 8-Iso: 8-Isoprostane.
tAble 5 spearman coefficent correlation Between parathyroiD hormone levels anD laBoratorial Data   
 assesseD in the stuDy population
PTH IL-1 IL-6 TNF-α MDA TRAP NOx AOPP FOX 8-Iso
Correlation 
coeficiente
0.047 -0.126 0.076 0.072 -0.112 0.060 0.118 0.079 0.043
Significancy 0.591 0.148 0.389 0.412 0.202 0.492 0.179 0.369 0.622
PTH: Parathyroid Hormone; IL-1 and 6: Interleukin 1 and 6; TNF-α: Tumor Necrosis Factor alpha; MDA: Malonic Dialdehyde; TRAP: Total Plasma 
Antioxidant Capacity (corrected for serum uric acid); NOx: Nitric Oxide metabolites; AOPP: Advanced Oxidation Protein Products; FOX: Lipid 
Hydroperoxidation; 8-Iso: 8-Isoprostane.
state is based on the increase in intracellular and 
mitochondrial free calcium - the calcium paradox -, 
which favors the production and release of ROS. In 
subjects undergoing states of aldosteronism (found, 
for example, in patients with congestive heart 
failure), excessive urinary loss of divalent cations 
such as calcium and magnesium occurs. These losses 
lead to the development of SHPT in an attempt to 
correct these losses. The high levels of PTH in this 
situation promote, despite normal or low serum 
calcium, large increase in intracellular calcium and 
increased ROS levels.15,16 Increased intracellular 
calcium and ROS open mitochondrial channels, 
causing swelling and mitochondrial dysfunction, with 
subsequent evolution to cellular necrosis. The repair 
process of this cardiomyocyte necrosis evolves with 
areas of myocardial fibrosis, thus increasing the risk 
of heart disease in this population (left ventricular 
hypertrophy, arrhythmias, and heart failure). Vidal 
et al.15 demonstrated that aldosterone infusion in 
rats previously submitted to parathyroidectomy 
prevented aldosterone induced increase in oxidative 
(H2O2 production by monocytes) and nitrosative (α1-
antiproteinase activity in plasma) stress.
In the present study, PTH levels did not correlate 
with EPO dosage and some laboratory tests routinely 
performed in hemodialysis patients, such as hemoglobin, 
ferritin, calcium, vitamin D, or albumin, but did positively 
correlate with phosphorus and alkaline phosphatase, this 
one a known marker of bone remodeling related to SHPT 
severity.30 Di Marco et al.31 showed that endothelial cell 
lines exposed to high phosphate concentrations, similar 
to phosphate levels found in uremic patients, have 
generated reactive oxygen species in vitro. The lack of 
correlation between PTH levels and hemoglobin or EPO 
dose is somewhat surprising, because primary32,33 and 
secondary34,35 HPT are classically associated with anemia, 
as PTH may directly inhibit erythropoiesis and induce 
bone marrow fibrosis.36
PTH levels were not associated with albumin, 
an indicator of nutritional status and a negative 
marker of inflammation, neither with vitamin D. 
Regarding PTH and vitamin D, two other studies 
have shown no or only weak correlations between 
these biomarkers in CKD patients and the general 
population.37,38 In the same line, some clinical trials 
showed only a slight reduction in PTH levels with 
replacement therapy with ergocalciferol in CKD.39,40 
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In contrast, Gracia-Iguacel et al.,41 in a population 
of dialysis patients (hemodialysis, hemodiafiltration, 
and peritoneal dialysis) f ound, in univariate analysis, 
a negative correlation between PTH and vitamin D.
The relationship between inflammation, oxidative 
stress, and the SHPT of hemodialysis patients is of 
great scientific interest. Although the present study 
was not the first to examine this relationship in these 
patients, it is the largest reported*. For evaluation of 
ROS, we used, as recommended, a panel of biomarkers 
rather than a specific marker, using well-established 
measurement techniques and seeking to exclude from 
the analysis patients or conditions that could interfere 
with ROS generation or the inflammatory state. It is 
known that parenteral iron and EPO agents, as well 
as temporary vascular access and infections, may 
exacerbate the inflammatory state.34
One important limitation of the study is its cross-
sectional nature, which prevents the determination 
of the relationship between cause and effect. Other 
limitation is the rather limited breadth of the panel 
of oxidative stress biomarkers used in the study. 
Finally, we did not put in our trial a control group 
for comparison of values of inflammation and 
oxidative stress in non-CKD population because, in 
our understanding, many other trials have shown the 
relationship between kidney disease and increased 
levels of these biomarkers.42-44
conclusIon
Despite the evidences of a relationship between 
hyperparathyroidism, the calcium paradox, and ROS/
inflammation, this study was not able to identify 
a significant correlation among PTH levels and 
biomarkers of inflammation and oxidative stress in 
chronic hemodialysis patients. It is well known that 
CKD patients present a state of increased inflammation 
and ROS that have multifactorial genesis. This could 
explain, in part, the findings of this study. In other 
words, our results may suggest that the inflammation 
and oxidative stress of hemodialysis patients probably 
arise from other mechanisms than secondary 
hyperparathyroidism, or that it contributes very little to 
the genesis of these phenomena.
acknowleDgements
The authors thank the Research and Postgraduate 
laboratory for the material support making possible 
the execution of this study.
RefeRences
 1. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease 
in chronic renal failure. J Am Soc Nephrol 1999;10:1606-15.
 2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, 
Chertow GM. Mineral metabolism, mortality, and morbidity in 
maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18. 
DOI: http://dx.doi.org/10.1097/01.ASN.0000133041.27682.
A2
 3. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner 
C, Zoccali C. Oxidative stress in end-stage renal disease: an 
emerging threat to patient outcome. Nephrol Dial Transplant 
2003;18:1272-80. DOI: http://dx.doi.org/10.1093/ndt/gfg074
 4.  Schiepatti A, Pisoni R, Remuzzi G. Pathophysiology and man-
agement of chronic kidney disease. In: Greenberg A, Cheung 
Ak, Coffman TM, Falk RJ, Jennette JC, eds. Primer on Kidney 
Diseases. 4th ed. Philadelphia: Elsevier Saunders; 2005. p.444-
54.
 5. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physi-
ol 1997;82:291-5. PMID: 9129943 
 6. Handelman GJ. Evaluation of oxidant stress in dialysis pa-
tients. Blood Purif 2000;18:343-9. DOI: http://dx.doi.
org/10.1159/000014460
 7. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysis-in-
duced oxidative stress: biological aspects, clinical consequenc-
es, and therapy. Semin Dial 2001;14:193-9. DOI: http://dx.doi.
org/10.1046/j.1525-139X.2001.00052.x
 8. Himmelfarb J, McMonagle E. Manifestations of oxidant stress 
in uremia. Blood Purif 2001;19:200-5. DOI: http://dx.doi.
org/10.1159/000046941
9. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama 
L, Lambrey G, et al. Oxidative stress and haemodialysis: role of 
inflammation and duration of dialysis treatment. Nephrol Dial 
Transplant 2001;16:335-40. DOI: http://dx.doi.org/10.1093/
ndt/16.2.335
10. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress 
in haemodialysis patients receiving intravenous iron therapy. 
Nephrol Dial Transplant 1999;14:2680-7. PMID: 10534512 
DOI: http://dx.doi.org/10.1093/ndt/14.11.2680
11. Cheng SP, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between 
parathyroid hormone levels and inflammatory markers among 
US adults. Mediators Inflamm 2014;2014:709024. DOI: http://
dx.doi.org/10.1155/2014/709024
12. Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, In-
sogna K. Circulating levels of interleukin-6 and tumor necrosis 
factor-alpha are elevated in primary hyperparathyroidism and 
correlate with markers of bone resorption-a clinical research 
center study. J Clin Endocrinol Metab 1996;81:3450-4. PMID: 
8855783
13. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, 
Insogna K. Circulating levels of interleukin-6 soluble receptor 
predict rates of bone loss in patients with primary hyperpara-
thyroidism. J Clin Endocrinol Metab 2002;87:4946-51. PMID: 
12414855 DOI: http://dx.doi.org/10.1210/jc.2001-011814
14. Emam AA, Mousa SG, Ahmed KY, Al-Azab AA. Inflamma-
tory biomarkers in patients with asymptomatic primary hyper-
parathyroidism. Med Princ Pract 2012;21:249-53. DOI: http://
dx.doi.org/10.1159/000334588
15. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, 
Weber KT. Calcium paradox of aldosteronism and the role 
of the parathyroid glands. Am J Physiol Heart Circ Physiol 
2006;290:H286-94. PMID: 16373592
16. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, 
Xing Z, et al. Hyperparathyroidism and the calcium paradox of 
aldosteronism. Circulation 2005;111:871-8. PMID: 15710759 
DOI: http://dx.doi.org/10.1161/01.CIR.0000155621.10213.06
17. Tanaka M, Tokunaga K, Maruyama T, Otagiri M, Tominaga 
Y, Itoh K, et al. Parathyroidectomy markedly reduces oxida-
tive stress in a patient with primary hyperparathyroidism. Ther 
Apher Dial 2011;15:38-41. DOI: http://dx.doi.org/10.1111/
j.1744-9987.2011.00925.x
J Bras Nefrol 2016;38(3):288-295
Parathyroid hormone, inflammation and oxidative stress
295
18. Navarro-González JF, Mora-Fernández C, Muros M, Herrera 
H, García J. Mineral metabolism and inflammation in chronic 
kidney disease patients: a cross-sectional study. Clin J Am Soc 
Nephrol 2009;4:1646-54. DOI: http://dx.doi.org/10.2215/
CJN.02420409
19. Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vester-
gaard H. Increased plasma N-terminal pro-B-type natriuretic 
peptide and markers of inflammation related to atherosclerosis 
in patients with primary hyperparathyroidism. Clin Endocri-
nol (Oxf) 2005;63(5):493-8. DOI:http://dx.doi.org/10.1111/
j.1365-2265.2005.02363.x
20. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, 
inflammation, and atherosclerosis (MIA) syndrome-the heart 
of the matter. Nephrol Dial Transplant 2002;17:28-31. DOI: 
http://dx.doi.org/10.1093/ndt/17.suppl_11.28
21. Noyan T, Avci G, Sekeroğlu MR, Erkoç R. The investigation of 
relationship between secondary hyperparathyroidism and oxi-
dative stress in patients with chronic kidney disease. Turk Neph 
Dial Transpl J 2009;18:69-75.
22. Wu CC, Chang JH, Chen CC, Su SB, Yang LK, Ma WY, et al. 
Calcitriol treatment attenuates inflammation and oxidative 
stress in hemodialysis patients with secondary hyperparathy-
roidism. Tohoku J Exp Med 2011;223:153-9. DOI: http://
dx.doi.org/10.1620/tjem.223.153
23. Lu KC, Tseng CF, Wu CC, Yeung LK, Chen JS, Chao TY, 
et al. Effects of calcitriol on type 5b tartrate-resistant acid 
phosphatase and interleukin-6 in secondary hyperparathy-
roidism. Blood Purif 2006;24:423-30. DOI: http://dx.doi.
org/10.1159/000094899
24. Jiang ZY, Woollard AC, Wolff SP. Lipid hydroperoxide mea-
surement by oxidation of Fe2+ in the presence of xylenol or-
ange. Comparison with the TBA assay and an iodometric meth-
od. Lipids 1991;26:853-6. PMID: 1795606 DOI: http://dx.doi.
org/10.1007/BF02536169
25. Navarro-Gonzálvez JA, García-Benayas C, Arenas J. Semiauto-
mated measurement of nitrate in biological fluids. Clin Chem 
1998;44:679-81. PMID:9510886
26. Repetto M, Reides C, Gomez Carretero ML, Costa M, Griem-
berg G, Llesuy S. Oxidative stress in blood of HIV infected 
patients. Clin Chim Acta 1996;255:107-17. PMID: 8937754 
DOI: http://dx.doi.org/10.1016/0009-8981(96)06394-2
27. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-
Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxida-
tion protein products as novel mediators of inflammation 
and monocyte activation in chronic renal failure. J Immunol 
1998;161:2524-32. PMID: 9725252
28. Bastos AS, Loureiro AP, de Oliveira TF, Corbi SC, Caminaga 
RM, Júnior CR, et al. Quantitation of malondialdehyde in gin-
gival crevicular fluid by a high-performance liquid chromatog-
raphy-based method. Anal Biochem 2012;423:141-6. PMID: 
22330745 DOI: http://dx.doi.org/10.1016/j.ab.2012.01.016
29. Almqvist EG, Bondeson AG, Bondeson L, Svensson J. Increased 
markers of inflammation and endothelial dysfunction in pa-
tients with mild primary hyperparathyroidism. Scand J Clin 
Lab Invest 2011;71:139-44. DOI: http://dx.doi.org/10.3109/0
0365513.2010.543694
30. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. 
Plasma total versus bone alkaline phosphatase as markers of 
bone turnover in hemodialysis patients. J Am Soc Nephrol 
1996;7:506-12.
31. Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Witt-
kowski W, Lang D, et al. Increased inorganic phosphate induc-
es human endothelial cell apoptosis in vitro. Am J Physiol Re-
nal Physiol 2008;294:F1381-7. PMID: 18385273 DOI: http://
dx.doi.org/10.1152/ajprenal.00003.2008
32. Falko JM, Guy JT, Smith RE, Mazzaferri EL. Primary hyper-
parathyroidism and anemia. Arch Intern Med 1976;136:887-
9. PMID: 949188 DOI:http://dx.doi.org/10.1001/
archinte.1976.03630080029010
33. Boxer M, Ellman L, Geller R, Wang CA. Anemia in prima-
ry hyperparathyroidism. Arch Intern Med 1977;137:588-
93. PMID: 857757 DOI:http://dx.doi.org/10.1001/
archinte.1977.03630170020008
34. Gallieni M, Corsi C, Brancaccio D. Hyperparathyroidism 
and anemia in renal failure. Am J Nephrol 2000;20:89-96. 
DOI:http://dx.doi.org/10.1159/000013563
35. Drüeke TB. R-HuEPO hyporesponsiveness-who and why? 
Nephrol Dial Transplant 1995;10:62-8
36. Drüeke T. Hyporesponsiveness to recombinant human eryth-
ropoietin. Nephrol Dial Transplant 2001;16:25-8. DOI:http://
dx.doi.org/10.1093/ndt/16.suppl_7.25
37. Petchey WG, Johnson DW, Hawley CM, Isbel NM. Predictors of 
vitamin D status in predialysis chronic kidney disease patients: a 
cross-sectional analysis in a high ultraviolet climate. J Ren Nutr 
2012;22:400-8. DOI: http://dx.doi.org/10.1053/j.jrn.2011.08.007
38. Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, 
Lappé DL, et al. Parathyroid hormone, vitamin D, renal dys-
function, and cardiovascular disease: dependent or independent 
risk factors? Am Heart J 2011;162:331-9.e2. PMID: 21835295 
DOI: http://dx.doi.org/10.1016/j.ahj.2011.05.005
39. Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ. 
Changes in serum 25-hydroxyvitamin D and plasma intact 
PTH levels following treatment with ergocalciferol in patients 
with CKD. Am J Kidney Dis 2007;50:59-68. PMID: 17591525 
DOI: http://dx.doi.org/10.1053/j.ajkd.2007.04.010
40.  Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of 
ergocalciferol treatment of vitamin D deficiency on serum 
parathyroid hormone concentrations in chronic kidney dis-
ease. Am J Nephrol 2007;27:36-43. DOI: http://dx.doi.
org/10.1159/000098561
41. Gracia-Iguacel C, Gallar P, Qureshi AR, Ortega O, Mon C, 
Ortiz M, et al. Vitamin D deficiency in dialysis patients: ef-
fect of dialysis modality and implications on outcome. J Ren 
Nutr 2010;20:359-67. DOI: http://dx.doi.org/10.1053/j.
jrn.2010.03.005
42. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow 
J, Ikizler TA, et al. Increased prevalence of oxidant stress and 
inflammation in patients with moderate to severe chronic kid-
ney disease. Kidney Int 2004;65:1009-16. DOI: http://dx.doi.
org/10.1111/j.1523-1755.2004.00465.x
43. Aveles PR, Criminácio CR, Gonçalves S, Bignelli AT, Claro LM, 
Siqueira SS, et al. Association between biomarkers of carbonyl 
stress with increased systemic inflammatory response in differ-
ent stages of chronic kidney disease and after renal transplanta-
tion. Nephron Clin Pract 2010;116:c294-9. PMID:20639676 
DOI: http://dx.doi.org/10.1159/000318792
44. Xu G, Luo K, Liu H, Huang T, Fang X, Tu W. The progress 
of inflammation and oxidative stress in patients with chronic 
kidney disease. Ren Fail 2015;37:45-9. DOI: http://dx.doi.org/
10.3109/0886022X.2014.964141
